<DOC>
	<DOCNO>NCT00075543</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , docetaxel oxaliplatin , work different way stop tumor cell divide stop grow die . Giving one drug may kill tumor cell . PURPOSE : This phase I/II trial study side effect best dose docetaxel oxaliplatin see well work treat patient stage III stage IV ovarian epithelial cancer .</brief_summary>
	<brief_title>Docetaxel Oxaliplatin Treating Patients With Stage III Stage IV Ovarian Epithelial Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine maximum tolerate dose docetaxel oxaliplatin patient stage III IV ovarian epithelial cancer . - Determine toxicity regimen patient . Secondary - Determine tolerance profile patient treat regimen . - Determine recommend phase III dose regimen patient . - Determine efficacy regimen , term objective response rate radiological biological response rate ( CA 125 ) , patient . - Determine complete pathological response patient treated regimen first-line therapy . - Determine duration objective response patient treat regimen . - Determine time progression patient treat regimen . OUTLINE : This dose-escalation , multicenter study . Patients receive docetaxel IV 1 hour oxaliplatin IV 2 hour day 1 . Treatment repeat every 3 week 6 course absence disease progression unacceptable toxicity . Patients follow monthly 3 month . PROJECTED ACCRUAL : A total 30-39 patient accrue study .</detailed_description>
	<mesh_term>Neoplasms , Glandular Epithelial</mesh_term>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm ovarian epithelial cancer Stage III IV disease Metastatic peritoneal , lymphatic , visceral disease Measurable evaluable disease Previously untreated disease OR relapse disease 6 month completion platinumcontaining chemotherapy regimen No symptomatic brain metastasis PATIENT CHARACTERISTICS : Age 18 75 Performance status WHO 02 ( 0 patient 70 75 year age ) Life expectancy Not specify Hematopoietic Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hepatic Bilirubin great 1.25 time upper limit normal ( ULN ) AST ALT great 3 time ULN Alkaline phosphatase less 2.5 time ULN Renal Creatinine great 1.4 mg/dL Other No serious uncontrolled infection No intolerance polysorbate 80 No peripheral neuropathy great grade 1 No neurological mental disease would preclude study participation No prior malignancy except curatively treat basal cell skin cancer carcinoma situ cervix PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy See Disease Characteristics More 4 week since prior chemotherapy No 1 prior chemotherapy regimen No prior oxaliplatin docetaxel Endocrine therapy Not specify Radiotherapy More 4 week since prior radiotherapy Surgery Not specify Other More 28 day since prior participation another clinical study No concurrent anticancer treatment</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2007</verification_date>
	<keyword>recurrent ovarian epithelial cancer</keyword>
	<keyword>stage III ovarian epithelial cancer</keyword>
	<keyword>stage IV ovarian epithelial cancer</keyword>
</DOC>